Mary Collins, PhD, is the Chief Scientific Officer for the Inflammation and Immunology Research Unit at Pfizer in Cambridge, Massachusetts. She has managerial and scientific responsibility for the discovery and development of new small molecule and protein therapeutics for the treatment of autoimmune and inflammatory diseases. Research interests include cytokine biology, lymphocyte activation, costimulatory receptors and innate immunity. She enjoys collaborative interactions with academic scientists in the Immunology community, making scientific contributions to the field, and mentoring scientists.